Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
19,709
Total Claims
$2.9M
Drug Cost
928
Beneficiaries
$3,126
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-97%
Opioid rate vs peers
0.1% vs 2.6% avg
+193%
Cost per patient vs peers
$3,126 vs $1,068 avg
+137%
Brand preference vs peers
21.3% vs 9.0% avg
Opioid Prescribing
0.1%
Opioid Rate
13
Opioid Claims
$48
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 4,140 claims · $2.5M
Generic: 15,272 claims · $391K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 259 | $278K |
| Empagliflozin | 349 | $260K |
| Dapagliflozin Propanediol | 244 | $218K |
| Apixaban | 291 | $207K |
| Dulaglutide | 191 | $181K |
| Tirzepatide | 126 | $131K |
| Rivaroxaban | 202 | $127K |
| Fluticasone/Umeclidin/Vilanter | 126 | $86K |
| Linagliptin | 75 | $57K |
| Insulin Glargine,hum.Rec.Anlog | 129 | $57K |
| Icosapent Ethyl | 88 | $48K |
| Linaclotide | 71 | $42K |
| Umeclidinium Brm/Vilanterol Tr | 71 | $37K |
| Empagliflozin/Metformin Hcl | 31 | $37K |
| Semaglutide | 27 | $32K |
Prescribing Profile
Patient Profile
69
Avg Age
66%
Female
1.52
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data